nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—Venous thrombosis—Carboplatin—ovarian cancer	0.0248	0.0544	CcSEcCtD
Dihydroxyaluminium—VDAC3—myometrium—ovarian cancer	0.0243	0.0446	CbGeAlD
Dihydroxyaluminium—VDAC1—myometrium—ovarian cancer	0.0231	0.0424	CbGeAlD
Dihydroxyaluminium—VDAC2—epithelium—ovarian cancer	0.0229	0.042	CbGeAlD
Dihydroxyaluminium—VDAC2—uterine cervix—ovarian cancer	0.0227	0.0417	CbGeAlD
Dihydroxyaluminium—Fluid overload—Carboplatin—ovarian cancer	0.0215	0.0472	CcSEcCtD
Dihydroxyaluminium—VDAC2—gonad—ovarian cancer	0.019	0.035	CbGeAlD
Dihydroxyaluminium—VDAC2—uterus—ovarian cancer	0.0189	0.0347	CbGeAlD
Dihydroxyaluminium—VDAC3—uterine cervix—ovarian cancer	0.0189	0.0347	CbGeAlD
Dihydroxyaluminium—VDAC1—epithelium—ovarian cancer	0.0181	0.0333	CbGeAlD
Dihydroxyaluminium—VDAC3—decidua—ovarian cancer	0.018	0.0331	CbGeAlD
Dihydroxyaluminium—VDAC1—uterine cervix—ovarian cancer	0.018	0.033	CbGeAlD
Dihydroxyaluminium—VDAC1—decidua—ovarian cancer	0.0171	0.0315	CbGeAlD
Dihydroxyaluminium—VDAC3—endometrium—ovarian cancer	0.0171	0.0314	CbGeAlD
Dihydroxyaluminium—VDAC2—female reproductive system—ovarian cancer	0.017	0.0312	CbGeAlD
Dihydroxyaluminium—Diuresis—Vinorelbine—ovarian cancer	0.0169	0.0371	CcSEcCtD
Dihydroxyaluminium—VDAC1—endometrium—ovarian cancer	0.0162	0.0299	CbGeAlD
Dihydroxyaluminium—VDAC3—gonad—ovarian cancer	0.0158	0.0291	CbGeAlD
Dihydroxyaluminium—VDAC3—uterus—ovarian cancer	0.0157	0.0289	CbGeAlD
Dihydroxyaluminium—VDAC2—female gonad—ovarian cancer	0.0154	0.0284	CbGeAlD
Dihydroxyaluminium—Extravasation—Carboplatin—ovarian cancer	0.0154	0.0337	CcSEcCtD
Dihydroxyaluminium—VDAC1—gonad—ovarian cancer	0.0151	0.0277	CbGeAlD
Dihydroxyaluminium—VDAC1—uterus—ovarian cancer	0.015	0.0275	CbGeAlD
Dihydroxyaluminium—VDAC3—female reproductive system—ovarian cancer	0.0141	0.026	CbGeAlD
Dihydroxyaluminium—TNNC1—endometrium—ovarian cancer	0.0139	0.0256	CbGeAlD
Dihydroxyaluminium—VDAC2—testis—ovarian cancer	0.0137	0.0252	CbGeAlD
Dihydroxyaluminium—VDAC1—female reproductive system—ovarian cancer	0.0135	0.0247	CbGeAlD
Dihydroxyaluminium—VDAC3—bone marrow—ovarian cancer	0.0134	0.0246	CbGeAlD
Dihydroxyaluminium—VDAC3—female gonad—ovarian cancer	0.0129	0.0237	CbGeAlD
Dihydroxyaluminium—VDAC3—vagina—ovarian cancer	0.0128	0.0235	CbGeAlD
Dihydroxyaluminium—VDAC1—bone marrow—ovarian cancer	0.0127	0.0234	CbGeAlD
Dihydroxyaluminium—Electrolyte imbalance—Vinorelbine—ovarian cancer	0.0126	0.0275	CcSEcCtD
Dihydroxyaluminium—VDAC1—female gonad—ovarian cancer	0.0122	0.0225	CbGeAlD
Dihydroxyaluminium—VDAC1—vagina—ovarian cancer	0.0122	0.0224	CbGeAlD
Dihydroxyaluminium—VDAC3—testis—ovarian cancer	0.0114	0.021	CbGeAlD
Dihydroxyaluminium—Phlebitis—Carboplatin—ovarian cancer	0.0113	0.0247	CcSEcCtD
Dihydroxyaluminium—VDAC1—testis—ovarian cancer	0.0109	0.02	CbGeAlD
Dihydroxyaluminium—VDAC2—lymph node—ovarian cancer	0.00993	0.0183	CbGeAlD
Dihydroxyaluminium—TNNC1—testis—ovarian cancer	0.0093	0.0171	CbGeAlD
Dihydroxyaluminium—Lung disorder—Topotecan—ovarian cancer	0.00867	0.019	CcSEcCtD
Dihydroxyaluminium—Electrolyte imbalance—Paclitaxel—ovarian cancer	0.00845	0.0185	CcSEcCtD
Dihydroxyaluminium—VDAC3—lymph node—ovarian cancer	0.00827	0.0152	CbGeAlD
Dihydroxyaluminium—VDAC1—lymph node—ovarian cancer	0.00787	0.0145	CbGeAlD
Dihydroxyaluminium—Vertigo—Altretamine—ovarian cancer	0.00762	0.0167	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Vinorelbine—ovarian cancer	0.00742	0.0163	CcSEcCtD
Dihydroxyaluminium—Convulsion—Altretamine—ovarian cancer	0.00735	0.0161	CcSEcCtD
Dihydroxyaluminium—Extravasation—Topotecan—ovarian cancer	0.00703	0.0154	CcSEcCtD
Dihydroxyaluminium—Extravasation—Melphalan—ovarian cancer	0.00689	0.0151	CcSEcCtD
Dihydroxyaluminium—TNNC1—lymph node—ovarian cancer	0.00674	0.0124	CbGeAlD
Dihydroxyaluminium—Venous thrombosis—Paclitaxel—ovarian cancer	0.00654	0.0143	CcSEcCtD
Dihydroxyaluminium—Extravasation—Vinorelbine—ovarian cancer	0.00602	0.0132	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Paclitaxel—ovarian cancer	0.0055	0.0121	CcSEcCtD
Dihydroxyaluminium—Infection—Carboplatin—ovarian cancer	0.00475	0.0104	CcSEcCtD
Dihydroxyaluminium—Dizziness—Altretamine—ovarian cancer	0.00458	0.01	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Vinorelbine—ovarian cancer	0.00442	0.00969	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Vinorelbine—ovarian cancer	0.0044	0.00965	CcSEcCtD
Dihydroxyaluminium—Vomiting—Altretamine—ovarian cancer	0.0044	0.00964	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Melphalan—ovarian cancer	0.00438	0.0096	CcSEcCtD
Dihydroxyaluminium—Polyuria—Vinorelbine—ovarian cancer	0.00434	0.00951	CcSEcCtD
Dihydroxyaluminium—Nausea—Altretamine—ovarian cancer	0.00411	0.00901	CcSEcCtD
Dihydroxyaluminium—Pain—Carboplatin—ovarian cancer	0.00409	0.00896	CcSEcCtD
Dihydroxyaluminium—Extravasation—Paclitaxel—ovarian cancer	0.00405	0.00887	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Vinorelbine—ovarian cancer	0.00383	0.00838	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Carboplatin—ovarian cancer	0.00378	0.00828	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Epirubicin—ovarian cancer	0.00374	0.0082	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Doxorubicin—ovarian cancer	0.00346	0.00758	CcSEcCtD
Dihydroxyaluminium—Extravasation—Docetaxel—ovarian cancer	0.00343	0.00752	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Vinorelbine—ovarian cancer	0.00321	0.00703	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Paclitaxel—ovarian cancer	0.00316	0.00692	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Topotecan—ovarian cancer	0.00309	0.00677	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Paclitaxel—ovarian cancer	0.00297	0.00652	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Paclitaxel—ovarian cancer	0.00296	0.00649	CcSEcCtD
Dihydroxyaluminium—Polyuria—Paclitaxel—ovarian cancer	0.00292	0.0064	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Epirubicin—ovarian cancer	0.00285	0.00625	CcSEcCtD
Dihydroxyaluminium—Chills—Topotecan—ovarian cancer	0.00276	0.00606	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Paclitaxel—ovarian cancer	0.0027	0.00593	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Docetaxel—ovarian cancer	0.00268	0.00587	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—ovarian cancer	0.00264	0.00578	CcSEcCtD
Dihydroxyaluminium—Convulsion—Chlorambucil—ovarian cancer	0.00261	0.00572	CcSEcCtD
Dihydroxyaluminium—Back pain—Topotecan—ovarian cancer	0.00259	0.00569	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Paclitaxel—ovarian cancer	0.00257	0.00564	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Docetaxel—ovarian cancer	0.00252	0.00553	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Docetaxel—ovarian cancer	0.00251	0.0055	CcSEcCtD
Dihydroxyaluminium—Infection—Chlorambucil—ovarian cancer	0.00244	0.00535	CcSEcCtD
Dihydroxyaluminium—Dehydration—Paclitaxel—ovarian cancer	0.00238	0.00522	CcSEcCtD
Dihydroxyaluminium—Extravasation—Epirubicin—ovarian cancer	0.00231	0.00507	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Epirubicin—ovarian cancer	0.0023	0.00503	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Docetaxel—ovarian cancer	0.00229	0.00502	CcSEcCtD
Dihydroxyaluminium—Convulsion—Melphalan—ovarian cancer	0.00228	0.00499	CcSEcCtD
Dihydroxyaluminium—Back pain—Vinorelbine—ovarian cancer	0.00222	0.00486	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Docetaxel—ovarian cancer	0.00218	0.00478	CcSEcCtD
Dihydroxyaluminium—Infection—Topotecan—ovarian cancer	0.00217	0.00477	CcSEcCtD
Dihydroxyaluminium—Oedema—Melphalan—ovarian cancer	0.00214	0.0047	CcSEcCtD
Dihydroxyaluminium—Extravasation—Doxorubicin—ovarian cancer	0.00214	0.00469	CcSEcCtD
Dihydroxyaluminium—Infection—Melphalan—ovarian cancer	0.00213	0.00467	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—ovarian cancer	0.00213	0.00466	CcSEcCtD
Dihydroxyaluminium—Pain—Chlorambucil—ovarian cancer	0.0021	0.00461	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Melphalan—ovarian cancer	0.00209	0.00458	CcSEcCtD
Dihydroxyaluminium—Vertigo—Vinorelbine—ovarian cancer	0.00206	0.00452	CcSEcCtD
Dihydroxyaluminium—Dehydration—Docetaxel—ovarian cancer	0.00202	0.00443	CcSEcCtD
Dihydroxyaluminium—Hypotension—Melphalan—ovarian cancer	0.002	0.00439	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Epirubicin—ovarian cancer	0.00196	0.0043	CcSEcCtD
Dihydroxyaluminium—Urticaria—Chlorambucil—ovarian cancer	0.00195	0.00428	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Chlorambucil—ovarian cancer	0.00194	0.00426	CcSEcCtD
Dihydroxyaluminium—Pain—Topotecan—ovarian cancer	0.00187	0.0041	CcSEcCtD
Dihydroxyaluminium—Infection—Vinorelbine—ovarian cancer	0.00186	0.00408	CcSEcCtD
Dihydroxyaluminium—Coma—Epirubicin—ovarian cancer	0.00184	0.00404	CcSEcCtD
Dihydroxyaluminium—Pain—Melphalan—ovarian cancer	0.00183	0.00402	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Docetaxel—ovarian cancer	0.00183	0.00401	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Vinorelbine—ovarian cancer	0.00183	0.00401	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—ovarian cancer	0.00181	0.00397	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Chlorambucil—ovarian cancer	0.00181	0.00397	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Paclitaxel—ovarian cancer	0.00178	0.0039	CcSEcCtD
Dihydroxyaluminium—Hypotension—Vinorelbine—ovarian cancer	0.00175	0.00384	CcSEcCtD
Dihydroxyaluminium—Urticaria—Topotecan—ovarian cancer	0.00174	0.00381	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Topotecan—ovarian cancer	0.00173	0.00379	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Paclitaxel—ovarian cancer	0.00171	0.00374	CcSEcCtD
Dihydroxyaluminium—Coma—Doxorubicin—ovarian cancer	0.00171	0.00374	CcSEcCtD
Dihydroxyaluminium—Urticaria—Melphalan—ovarian cancer	0.0017	0.00373	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Epirubicin—ovarian cancer	0.0017	0.00373	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Epirubicin—ovarian cancer	0.00169	0.00371	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Chlorambucil—ovarian cancer	0.00168	0.00369	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Topotecan—ovarian cancer	0.00161	0.00353	CcSEcCtD
Dihydroxyaluminium—Pain—Vinorelbine—ovarian cancer	0.0016	0.00351	CcSEcCtD
Dihydroxyaluminium—Chills—Paclitaxel—ovarian cancer	0.00159	0.00349	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Melphalan—ovarian cancer	0.00158	0.00346	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—ovarian cancer	0.00157	0.00345	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—ovarian cancer	0.00157	0.00343	CcSEcCtD
Dihydroxyaluminium—Vomiting—Chlorambucil—ovarian cancer	0.00156	0.00343	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Docetaxel—ovarian cancer	0.00151	0.0033	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Topotecan—ovarian cancer	0.0015	0.00328	CcSEcCtD
Dihydroxyaluminium—Back pain—Paclitaxel—ovarian cancer	0.00149	0.00327	CcSEcCtD
Dihydroxyaluminium—Urticaria—Vinorelbine—ovarian cancer	0.00149	0.00326	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Vinorelbine—ovarian cancer	0.00148	0.00324	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Epirubicin—ovarian cancer	0.00147	0.00322	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Melphalan—ovarian cancer	0.00147	0.00321	CcSEcCtD
Dihydroxyaluminium—Nausea—Chlorambucil—ovarian cancer	0.00146	0.0032	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Paclitaxel—ovarian cancer	0.00145	0.00319	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Docetaxel—ovarian cancer	0.00145	0.00317	CcSEcCtD
Dihydroxyaluminium—Dizziness—Topotecan—ovarian cancer	0.00145	0.00317	CcSEcCtD
Dihydroxyaluminium—Vomiting—Topotecan—ovarian cancer	0.00139	0.00305	CcSEcCtD
Dihydroxyaluminium—Vertigo—Paclitaxel—ovarian cancer	0.00139	0.00304	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Vinorelbine—ovarian cancer	0.00138	0.00302	CcSEcCtD
Dihydroxyaluminium—Vomiting—Melphalan—ovarian cancer	0.00136	0.00299	CcSEcCtD
Dihydroxyaluminium—Dehydration—Epirubicin—ovarian cancer	0.00136	0.00299	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—ovarian cancer	0.00136	0.00298	CcSEcCtD
Dihydroxyaluminium—Chills—Docetaxel—ovarian cancer	0.00135	0.00296	CcSEcCtD
Dihydroxyaluminium—Convulsion—Paclitaxel—ovarian cancer	0.00134	0.00293	CcSEcCtD
Dihydroxyaluminium—Nausea—Topotecan—ovarian cancer	0.0013	0.00285	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vinorelbine—ovarian cancer	0.00128	0.00281	CcSEcCtD
Dihydroxyaluminium—Nausea—Melphalan—ovarian cancer	0.00127	0.00279	CcSEcCtD
Dihydroxyaluminium—Back pain—Docetaxel—ovarian cancer	0.00127	0.00277	CcSEcCtD
Dihydroxyaluminium—Dehydration—Doxorubicin—ovarian cancer	0.00126	0.00276	CcSEcCtD
Dihydroxyaluminium—Oedema—Paclitaxel—ovarian cancer	0.00126	0.00276	CcSEcCtD
Dihydroxyaluminium—Infection—Paclitaxel—ovarian cancer	0.00125	0.00274	CcSEcCtD
Dihydroxyaluminium—Dizziness—Vinorelbine—ovarian cancer	0.00124	0.00271	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Epirubicin—ovarian cancer	0.00123	0.0027	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Paclitaxel—ovarian cancer	0.00123	0.00269	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vinorelbine—ovarian cancer	0.00119	0.00261	CcSEcCtD
Dihydroxyaluminium—Hypotension—Paclitaxel—ovarian cancer	0.00118	0.00258	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—ovarian cancer	0.00114	0.0025	CcSEcCtD
Dihydroxyaluminium—Convulsion—Docetaxel—ovarian cancer	0.00113	0.00248	CcSEcCtD
Dihydroxyaluminium—Nausea—Vinorelbine—ovarian cancer	0.00111	0.00244	CcSEcCtD
Dihydroxyaluminium—Pain—Paclitaxel—ovarian cancer	0.00108	0.00236	CcSEcCtD
Dihydroxyaluminium—Oedema—Docetaxel—ovarian cancer	0.00107	0.00234	CcSEcCtD
Dihydroxyaluminium—Infection—Docetaxel—ovarian cancer	0.00106	0.00232	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Docetaxel—ovarian cancer	0.00104	0.00228	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Epirubicin—ovarian cancer	0.00102	0.00223	CcSEcCtD
Dihydroxyaluminium—Urticaria—Paclitaxel—ovarian cancer	0.001	0.00219	CcSEcCtD
Dihydroxyaluminium—Hypotension—Docetaxel—ovarian cancer	0.000998	0.00219	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Paclitaxel—ovarian cancer	0.000996	0.00218	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Epirubicin—ovarian cancer	0.000977	0.00214	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—ovarian cancer	0.00094	0.00206	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Paclitaxel—ovarian cancer	0.000928	0.00203	CcSEcCtD
Dihydroxyaluminium—Pain—Docetaxel—ovarian cancer	0.000913	0.002	CcSEcCtD
Dihydroxyaluminium—Chills—Epirubicin—ovarian cancer	0.000909	0.00199	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—ovarian cancer	0.000904	0.00198	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Paclitaxel—ovarian cancer	0.000862	0.00189	CcSEcCtD
Dihydroxyaluminium—Back pain—Epirubicin—ovarian cancer	0.000853	0.00187	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Docetaxel—ovarian cancer	0.000844	0.00185	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—ovarian cancer	0.000842	0.00184	CcSEcCtD
Dihydroxyaluminium—Dizziness—Paclitaxel—ovarian cancer	0.000833	0.00183	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Epirubicin—ovarian cancer	0.000832	0.00182	CcSEcCtD
Dihydroxyaluminium—Vomiting—Paclitaxel—ovarian cancer	0.000801	0.00176	CcSEcCtD
Dihydroxyaluminium—Vertigo—Epirubicin—ovarian cancer	0.000793	0.00174	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—ovarian cancer	0.00079	0.00173	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Docetaxel—ovarian cancer	0.000787	0.00172	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—ovarian cancer	0.000769	0.00169	CcSEcCtD
Dihydroxyaluminium—Convulsion—Epirubicin—ovarian cancer	0.000764	0.00168	CcSEcCtD
Dihydroxyaluminium—Nausea—Paclitaxel—ovarian cancer	0.000748	0.00164	CcSEcCtD
Dihydroxyaluminium—Vertigo—Doxorubicin—ovarian cancer	0.000734	0.00161	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Docetaxel—ovarian cancer	0.00073	0.0016	CcSEcCtD
Dihydroxyaluminium—Oedema—Epirubicin—ovarian cancer	0.00072	0.00158	CcSEcCtD
Dihydroxyaluminium—Infection—Epirubicin—ovarian cancer	0.000715	0.00157	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—ovarian cancer	0.000707	0.00155	CcSEcCtD
Dihydroxyaluminium—Dizziness—Docetaxel—ovarian cancer	0.000706	0.00155	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Epirubicin—ovarian cancer	0.000703	0.00154	CcSEcCtD
Dihydroxyaluminium—Vomiting—Docetaxel—ovarian cancer	0.000679	0.00149	CcSEcCtD
Dihydroxyaluminium—Hypotension—Epirubicin—ovarian cancer	0.000673	0.00147	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—ovarian cancer	0.000666	0.00146	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—ovarian cancer	0.000662	0.00145	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—ovarian cancer	0.00065	0.00143	CcSEcCtD
Dihydroxyaluminium—Nausea—Docetaxel—ovarian cancer	0.000634	0.00139	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—ovarian cancer	0.000623	0.00136	CcSEcCtD
Dihydroxyaluminium—Pain—Epirubicin—ovarian cancer	0.000616	0.00135	CcSEcCtD
Dihydroxyaluminium—Urticaria—Epirubicin—ovarian cancer	0.000572	0.00125	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—ovarian cancer	0.00057	0.00125	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Epirubicin—ovarian cancer	0.000569	0.00125	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Epirubicin—ovarian cancer	0.000531	0.00116	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—ovarian cancer	0.000529	0.00116	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—ovarian cancer	0.000527	0.00115	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Epirubicin—ovarian cancer	0.000493	0.00108	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—ovarian cancer	0.000491	0.00108	CcSEcCtD
Dihydroxyaluminium—Dizziness—Epirubicin—ovarian cancer	0.000476	0.00104	CcSEcCtD
Dihydroxyaluminium—Vomiting—Epirubicin—ovarian cancer	0.000458	0.001	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—ovarian cancer	0.000456	0.000999	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—ovarian cancer	0.000441	0.000966	CcSEcCtD
Dihydroxyaluminium—Nausea—Epirubicin—ovarian cancer	0.000428	0.000937	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—ovarian cancer	0.000424	0.000928	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—ovarian cancer	0.000396	0.000867	CcSEcCtD
